products-page-bottom-left-box

Avis

Al-Tinez Pharmaceuticals Limited
9, Olowogbowo Str off Obokun Str by Coker Rd, Ilupeju, Lagos
Tel: 01-4826452; 0802-307-7320, 0803-305-7978

Brand Name

Avis

Manufacturer

Plethico Pharmaceuticals Limited, A.B Road, Mangilia - 453 771 Indore (M.P), India.

Therapeutic Class

Anthelmintics

Dosage Form, Composition & NAFDAC Registration Number (NRN)

Tablet (NRN: 04-3713): Albendazole 400 mg.

How to Identify the Product: Orange coloured film-coated oblong tablet.

Pack size: Blister pack of 1 tablet.

Pharmacology

Animal and human studies have that Albendazole exhibits vermicidal, ovicidal and larvacidal activity.

The principal mode of action for albendazole is by its inhibitory effect on tubulin polymerization, which results in the loss of cytoplasmic microtubules.

Indications

Treatment of the following infestations:

  • Roundworms (Ascaris lumbricoides), whipworm (Trichuris trichuria), pinworm or threadworm (Enterobius vermicularis), hookworm (Ancyclostoma duodenale and Necator americanus) and Strongyloides stercoralis, Taenia solium and Taenia saginata, and Opisthorchis viverrini.
  • Neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm
  • Hydatid disease of the liver, lung, and peritoneum, casued by the larval form of the dog tapeworm, Echinococcus granulosus.

Contra-indications

  • Albendazole should not be administered during pregnancy or in women thought to be pregnant.
  • In patients with known hypersensitivity to the benzimidazole class of compounds.

Precautions/Warnings

Rare fatalities associated with the use of albendazole are reported due to granulocytopenia or pancytopenia. Blood counts should be monitored at the beginning of each 28-day cycle of therapy, and every 2 weeks while on therapy with albendazole.

Patients being treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy if required.

Before initiating therapy for neurocysticercosis, the patient should be examined for the presence of retinal lesions. Need for anticysticeral therapy should be weighed against the possibility of retinal damage caused by albendazole.

During albendazole therapy, because of the possibility of harm to the liver or bone marrow, routine (every 2 weeks) monitoring of blood counts and liver function tests should take place.

Pregnancy/Lactation:

Albendazole is contraindicated during pregnancy.

It is not known whether it is excreted in human milk. Hence, caution should be exercised when albendazole is administered to a nursing woman.

Interactions

Concentration of albendazole sulfoxide is found to be about 56% higher when 8 mg dexamethasone is coadministered.

Coadministration of praziquantel (40 mg/kg) increases plasma concentration of albendazole sulfoxide by about 50%.

The pharmacokinetics of praziquantel are unchanged following coadministration with albendazole.

Albendazole sulfoxide concentrations in bile and cystic fluid are increased to about 2-fold when coadministered with cimetidine

The pharmacokinetics of theophylline remains unchanged when coadministered with albendazole.

Adverse Effects

Albendazole is well-tolerated drug. Following are the common adverse effects related to albendazole:

  • Epigastric pains, diarrhea, headache, nausea, vomiting, dizziness, constipation, pruritus, dry mouth, elevated liver transaminases.
  • Other rare adverse effects are: raised intracranial pressure, meningeal signs, allergic reactions (hypersensitivity), reversible alopecia, leukopenia, granulocytopenia, pancytopenia, agranulocytosis, thrombocytopenia.

Dosage & Administration

Hydatid Disease: Adults and Children

By mouth: For patients weighing 60 kg or more, 400 mg twice daily with meals for a 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles.

For patients weighing less than 60 kg, 15 mg/kg/day in divided doses twice daily with meals (max. 800 mg/day) for a 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles.

In the presurgical or postsurgical setting, optimal killing of cyst contents is achieved with 3 courses of therapy.

Neurocysticercosis: Adults and Children

By mouth: For patients weighing 60 kg or more, 400 mg twice daily with meals for 8 to 30 days.

For patients weighing less than 60 kg, 15 mg/kg/day in divided doses twice daily with meals (max, 800 mg/day) for 8 to 30 days.

Storage/Handling Recommendations

Store in a dry place below 25ºC. Protect from direct sunlight.

Keep out of reach of children.

Review Date

2016-12-02 07:16:06